在两个第一阶段试验 (MTN-030/IPM 041和MTN-044/IPM 053/CCN019) 中,达皮维林莱沃诺格斯特勒阴道环的可接受性:对多用途预防技术开发的影响
Barbara A Friedland1, Holly Gundacker2, Sharon L Achilles3,4
1Center for Biomedical Research, Population Council, New York, NY, United States of America.
PloS one
|January 14, 2025
概括
达皮维林-莱沃诺格斯特雷尔环 (DPV-LNG) 显示出同时预防艾滋病毒和怀孕的前景. 解决出血和排泄问题是提高用户接受这种多用途技术的关键.
科学领域:
- 生殖健康 生殖健康
- 预防传染病 预防传染病
- 药理学 药理学是指药理学的学科.
背景情况:
- 多用途预防技术 (MPT) 对于解决同时存在的艾滋病毒和怀孕风险至关重要.
- 早期的最终用户反对于优化MPT至关重要,包括新的基于环的交付系统.
研究的目的:
- 为了评估90天的达比维林-莱沃诺格斯特雷尔环 (DPV-LNG) 使用14天的可接受性,与仅使用达比维林的环 (DVR-200mg) 相比.
- 评估DPV-LNG环使用90天周期性或连续的可接受性.
- 为了确定与这些环的可接受性相关的因素.
主要方法:
- 两项研究 (MTN-030/IPM 041和MTN-044/IPM 053/CCN019) 招募了18至45岁的HIV阴性女性.
- 参与者通过每日短信自我报告了阴道出血和粘附 (去除,驱逐).
- 在研究结束时通过面对面的采访来评估可接受性.
主要成果:
- 14天研究中的大多数参与者 (21/23) 喜欢他们的指定的戒指;90天研究中的大约一半 (13/25) 喜欢他们的.
- 在90天的研究中,不喜欢DPV-LNG环与意外的阴道出血增加有关,并报告出血变化是不可接受的.
- 不喜欢DPV-LNG环也与在上所时排泄的发生率更高有关,尽管整体遵守与可接受性没有显著关联.
结论:
- 据了解,DPV-LNG环节展示了女性寻求双重保护,防止艾滋病毒和意外怀孕的潜力.
- 改善产品特性以减轻阴道出血和排泄是提高DPV-LNG环的可接受性至关重要的.
- 早期的用户反集成对于MPT的成功开发至关重要.
相关概念视频
01:11Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
01:26Drug Administration and Therapy Phases: Overview
406
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
406
01:19Pharmacovigilance
770
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
770